Sponsored by Thermo Fisher Scientific
Institutional Lessons From Implementing Plasma Genotyping to Monitor Response and Treatment in Non-Small Cell Lung Cancer
Nearly 70 years after the discovery of cell-free DNA, plasma genotyping is routinely used to non-invasively detect and quantify clinically relevant point mutations, insertions/deletions, amplifications, rearrangements, and aneuploidy. Over the past eight-plus years, strong concordance has been shown between plasma and tissue-based genomic assays, encouraging the clinical adaptation of plasma genotyping. In this webinar, Dr. Cloud Paweletz will present institutional experiences implementing liquid biopsies into non-small cell lung cancer. He will discuss technical limitations and lessons learned with a particular focus on minimal residual disease, treatment response, and the emergence of resistance monitoring. The realization of these lessons, however, spurs significant investment in techniques and technologies to increase specificity and sensitivity and reduce turnaround time and cost for further clinical adoption of this promising diagnostic.
Sponsored by Beckman Coulter Life Sciences
Next-generation sequencing of infectious agents is crucial for large-scale genomic surveillance of infectious diseases. Throughout the SARS-CoV-2 pandemic, several consortia across the globe have coordinated efforts to understand the epidemiology of SARS-CoV-2 through the identification and tracking of novel variants in cases of positive patients. In this webinar, we highlight the collaboration between the European Molecular Biology Laboratory (EMBL), New England Biolabs (NEB), and Beckman Coulter Life Sciences to develop an automated high-throughput NGS library prep workflow for SARS-CoV-2 surveillance using the NEBNext ARTIC SARS-CoV-2 Library Prep Kit (Illumina) and the Biomek i7 Hybrid NGS Workstation.
Sponsored by Qiagen
The Association Between Diabetes and Latent TB Infection: The Role of Diagnostics in Improving Outcomes
Someone with untreated latent tuberculosis infection (LTBI) and diabetes is more likely to develop tuberculosis (TB) disease than someone without diabetes. Without proper treatment, diabetes and TB can increase health complications.
In this webinar, Dr. Sonia Qasba will journey through the epidemiology, risk, and treatment recommendations of diabetic patients with LTBI. She will discuss how diabetes potentiates TB and why TB predisposes one to hyperglycemia. Additionally, she will share real-life examples of screening, prevention, and treatment of individuals with LTBI, TB, and diabetes.
Sponsored by Congenica
The time and cost of genomic analysis create significant bottlenecks in clinical labs and are predicted to account for more than half the cost of the clinical use of next-generation sequencing by 2026. This is often a key concern as reimbursement for data interpretation can prove challenging.
Choosing a professional solution for genomic analysis and interpretation can significantly reduce data analysis time while increasing diagnostic yield. For labs that have invested time and money in developing their own customized genomic data analysis solutions, the decision to move to a professional solution can be a difficult one.
In this webinar, Anna Miller, technical specialist at NOAH Clinical Laboratory, will talk about her experience using both professional and in-house solutions. She will discuss the essential attributes needed in a professional solution to deliver significant benefits and return on investment. These include:
- Clinically standardized workflows - A platform that facilitates and supports recommended clinical practices.
- Flexibility - A platform that also enables on-demand integration of existing knowledge bases and historical reference data, allowing users to customize clinical workflows.
- Deployment flexibility - Offering solutions both on-premise and in the cloud.
- Efficiency - Providing automation of known variants and automatic classification of unknown variants to increase efficiency and yield.
- Scalability - Enabling users to scale operations from panels to exomes to genomes without implementing new tools.
- Clinically proven - Demonstrated ability to maximize diagnostic yield.
- Partnership - A company that has the knowledge and expertise to deliver the best possible service.
Sponsored by Talis Bio
Rapid and accurate point-of-care (POC) testing systems have the potential to improve patient triage and treatment, mitigate the spread of infectious diseases by rapidly identifying infected individuals, improve diagnostics when access to centralized labs is limited, and lower testing costs. The Talis One is a compact, sample-to-answer, and connection-ready molecular diagnostic instrument built with convenience, efficiency, and ease of use in mind. Each Talis One infectious disease test employs a single-use, self-contained, room temperature-stable test cartridge.
In this webinar, Dr. Glen Hansen, assistant professor in the Division of Infectious Disease at the University of Minnesota will:
- Discuss the benefits of POC testing for infectious diseases, e.g., respiratory infections, sexually transmitted infections, etc.
- Highlight how COVID-19 has changed adoption of and perspectives on POC testing.
- Share his preliminary experience using the Talis One COVID-19 Test System.
Dr. Matthew Faron, assistant professor at the Medical College of Wisconsin will:
- Discuss the design, performance, and infectious disease menu for the Talis One system.
- Review preliminary data and personal experience in using the Talis One COVID-19 Test System.
Sponsored by SeraCare
Laboratory Adoption and Clinical Considerations for Prenatal Cell-Free DNA Screening for Common Aneuploidies
Cell-free (cf)DNA screening of pregnancies (also known as non-invasive prenatal testing or NIPT) is a transformative technology that is becoming routine for all pregnancies. Laboratories are potentially faced with adding a new technological approach in order to add NIPT to their repertoire of assays. Laboratories may choose from whole-genome NGS methods or more targeted methods. Furthermore, there are evolving regulatory requirements, a lack of test standardization around the world, and few validation studies targeting rare disorders. Clinical laboratory directors also need to anticipate the complexities of interpreting results from an inconclusive finding or disentangling biological considerations such as placental mosaicism from analytical performance considerations. However, NIPT is still a screening test, and thus confirmation by amniocentesis or chorionic villus sampling and diagnostic testing is required.
In this webinar, expert panelists, Jillian Buchan, PhD FACMG; Glenn Palomaki PhD; Kaarel Krjutškov PhD; and Russell Garlick, PhD will discuss recent experiences adopting NIPT testing for routine use, designing and executing complex validation studies, and interpreting unexpected results.
Panelist presentations will be followed by a discussion of current topics and audience questions.
Sponsored by Tecan
The use of next-generation sequencing (NGS) technologies in the field of infectious diseases has transformed the way pathogens are detected and characterized. Metagenomic sequencing provides a comprehensive and high-resolution analysis of microbial genetic material including bacteria, fungi, viruses, and parasites that is independent from microbial culture. The main challenge of developing a metagenomic sequencing assay is the efficient and unbiased recovery of microbial nucleic acids from degraded samples.
The Karius Test is a liquid biopsy that can non-invasively and rapidly detect over 1,000 pathogens from a single blood sample. When developing the Karius Test, scientists at Karius not only encountered challenges unique to metagenomics but unique to the biomarker that makes the test non-invasive; microbial cell-free DNA (mcfDNA). These challenges include working with degraded samples, unbiased detection of all mcfDNA in the sample, removing host and contaminant nucleic acid, and a streamlined workflow that accommodates a fast turnaround time. Tecan’s patented NGS library preparation technologies have supported laboratories like Karius to develop transformative genomic assays that uncover insights from even the most challenging samples.
In this webinar, Dr. Tim Blauwkamp, Chief Scientific Officer at Karius will discuss:
- Challenges in developing a cell-free DNA metagenomic sequencing assay.
- Approaches to solving these challenges for a liquid biopsy test for infectious diseases.
- Collaboration with Tecan to recover fragments efficiently and without bias in degraded samples.
Tecan genomics reagents are for Research Use Only. Not for diagnostic procedures.
The Karius Test was developed and its performance characteristics determined by Karius. This test has not been cleared or approved by the FDA, nor is it required to be. The Karius laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) and is accredited by the College of American Pathologists (CAP) to perform high-complexity clinical laboratory testing.
Sponsored by PerkinElmer
Liquid biopsy assays that analyze circulating tumor DNA in a cancer patient's blood stream have gained traction in recent years, presenting an attractive alternative to current methods for measuring treatment response, monitoring relapse, and predicting outcomes.
With ctDNA testing becoming more established in therapy selection for advanced cancer, the field is now poised to break into new areas, such as the detection of minimal residual disease (MRD) in early-stage patients. Our panel of pioneers in the field of cell-free cancer DNA testing will discuss the latest developments in ctDNA analysis and provide examples of its evolving use in colorectal, breast, lung, and other cancer types.